Takeda Ventures

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 73
Average round size
info
The average size of a deal this fund participated in
$38M
Portfolio companies 57
Rounds per year 3.65
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 15
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2001 was created Takeda Ventures, which is appeared as VC. The main office of represented VC is situated in the Palo Alto. The fund was located in North America if to be more exact in United States. Takeda Ventures seemed to be an CVC arrangement as part of the organization.

We also calculated 6 valuable employees in our database.

Among the most popular fund investment industries, there are Pharmaceutical, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Obsidian Therapeutics, Juventas Therapeutics, BIOMx Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Takeda Ventures performs on 13 percentage points less the average number of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2017. The increased amount of exits for fund were in 2019. Speaking about the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The typical startup value when the investment from Takeda Ventures is 5-10 millions dollars.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Takeda Ventures, startups are often financed by Sofinnova Partners, Forbion Capital Partners, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Boehringer Ingelheim Venture Fund, SR One. In the next rounds fund is usually obtained by Sofinnova Partners, Savitr Capital, Providence Investment Company Limited.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Takeda Ventures:
Typical Co-investors
Takeda Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Takeda Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Advance Newhouse -
Alchemy Group -
Armonia Connecticut, Greenwich, United States
BBC Worldwide England, London, United Kingdom
Carnegie Arch Capital -
CCINT China, Shanghai
Crown Castle Houston, Texas, United States
Enterprise Development Corporation of South Florida -
Goldwind Beijing, Beijing, China
Imaginary Ventures -
MITA Ventures Jalisco, Mexico, Puerto Vallarta
National Capital Fund Mazowieckie, Poland, Warszawa
Roca Junyent Barcelona, Catalonia, Spain
SenseTime Beijing, Beijing, China
Shenzhenshi Qianhai Hexiang Jijin China, Guangdong, Shenzhen
SV Tech Ventures California, Palo Alto, United States
The Oklahoman Oklahoma, Oklahoma City, United States
TOKAI-SOFT Japan, Shizuoka, Shizuoka Prefecture
True Blue Partners -
Viaduct Ventures California, Mountain View, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Integra Therapeutics

Biotechnology
Genetics
Health Care
$5M02 Dec 2021 Barcelona, Catalonia, Spain

Egle Therapeutics

Biotechnology
Health Care
Therapeutics
$47M22 Oct 2021 Paris, Ile-de-France, France

Turnstone Biologics

Biotechnology
Innovation Management
Therapeutics
$80M14 Jul 2021 San Francisco, California, United States

Transine Therapeutics

Biotechnology
Life Science
$12M01 Jun 2021 Cambridge, England, United Kingdom

Biotechnology
Therapeutics
$12M05 May 2021 Sunnyvale, California, United States

Seqster

Health Care
Medical
SaaS
Software
$12M22 Apr 2021 San Diego, California, United States

Code Biotherapeutics

Biotechnology
Life Science
$10M20 Apr 2021 Hatfield, Pennsylvania, United States

Adaptate Biotherapeutics

Biotechnology
Health Care
Therapeutics
$17M19 Apr 2021 London, Ontario, Canada

Arcellx

Biopharma
Health Care
Pharmaceutical
$115M13 Apr 2021 Maryland, United States
News
Turnstone Biologics Raises $80 Million Series D Financing

– Turnstone Biologics Corp. announced the successful completion of an $80m Series D financing co-led by PFM Health Sciences and Point72.
– New investors include Eventide Asset Management, Surveyor Capital (a Citadel company), Ridgeback Capital Investments, Takeda Ventures, CaaS Capital, JM Family Enterprises, Inc., Northleaf Capital Partners, 404 Bio and an undisclosed investor.
– The round was joined by existing investors Versant Ventures, OrbiMed, F-Prime Capital, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.
– Proceeds from the financing will be used to advance Turnstone’s pipeline of programs from its oncolytic virus and TIL therapy platforms.

Ribon Therapeutics Secures $65 Million Financing

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Takeda Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: